Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ZIOPHARM Oncology Inc Cancer Drug Fails Late-Stage Trial-Reuters


Tuesday, 26 Mar 2013 01:29pm EDT 

Reuters reported that ZIOPHARM Oncology Inc said it will stop developing its drug to treat soft tissue sarcoma after it failed to improve patient survival by keeping the cancer from worsening. The drug, palifosfamide, was being tested in a late-stage trial called Picasso 3 as a treatment for metastatic soft tissue sarcoma - a type of cancer of the bone, cartilage, fat or muscles. 

Company Quote

2.92
-0.05 -1.68%
19 Sep 2014